These findings demonstrate that low dose rapamycin treatment for a longer duration of time is most effective in the Tsc2+/- mouse, and it would be reasonable to evaluate this dosing strategy in future TSC clinical trials. Here, TSC2 is linked to tuberous sclerosis.